GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amphastar Pharmaceuticals Inc (FRA:29A) » Definitions » E10

Amphastar Pharmaceuticals (FRA:29A) E10 : €0.73 (As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Amphastar Pharmaceuticals E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Amphastar Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2024 was €0.745. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €0.73 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Amphastar Pharmaceuticals's average E10 Growth Rate was 25.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2024-06-09), Amphastar Pharmaceuticals's current stock price is €37.14. Amphastar Pharmaceuticals's E10 for the quarter that ended in Mar. 2024 was €0.73. Amphastar Pharmaceuticals's Shiller PE Ratio of today is 50.88.

During the past 13 years, the highest Shiller PE Ratio of Amphastar Pharmaceuticals was 114.20. The lowest was 14.35. And the median was 61.44.


Amphastar Pharmaceuticals E10 Historical Data

The historical data trend for Amphastar Pharmaceuticals's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amphastar Pharmaceuticals E10 Chart

Amphastar Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 0.56 0.62

Amphastar Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.57 0.49 0.62 0.62 0.73

Competitive Comparison of Amphastar Pharmaceuticals's E10

For the Drug Manufacturers - Specialty & Generic subindustry, Amphastar Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amphastar Pharmaceuticals's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Amphastar Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Amphastar Pharmaceuticals's Shiller PE Ratio falls into.



Amphastar Pharmaceuticals E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Amphastar Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.745/131.7762*131.7762
=0.745

Current CPI (Mar. 2024) = 131.7762.

Amphastar Pharmaceuticals Quarterly Data

per share eps CPI Adj_EPS
201406 -0.022 100.560 -0.029
201409 -0.093 100.428 -0.122
201412 -0.049 99.070 -0.065
201503 -0.009 99.621 -0.012
201506 -0.134 100.684 -0.175
201509 -0.062 100.392 -0.081
201512 0.156 99.792 0.206
201603 0.045 100.470 0.059
201606 0.134 101.688 0.174
201609 0.071 101.861 0.092
201612 -0.057 101.863 -0.074
201703 0.019 102.862 0.024
201706 0.036 103.349 0.046
201709 0.002 104.136 0.003
201712 0.025 104.011 0.032
201803 -0.122 105.290 -0.153
201806 -0.051 106.317 -0.063
201809 0.043 106.507 0.053
201812 0.035 105.998 0.044
201903 0.018 107.251 0.022
201906 0.850 108.070 1.036
201909 0.027 108.329 0.033
201912 -0.018 108.420 -0.022
202003 0.072 108.902 0.087
202006 -0.004 108.767 -0.005
202009 0.068 109.815 0.082
202012 -0.107 109.897 -0.128
202103 0.084 111.754 0.099
202106 0.133 114.631 0.153
202109 0.502 115.734 0.572
202112 0.345 117.630 0.386
202203 0.427 121.301 0.464
202206 0.312 125.017 0.329
202209 0.303 125.227 0.319
202212 0.623 125.222 0.656
202303 0.467 127.348 0.483
202306 0.452 128.729 0.463
202309 0.853 129.860 0.866
202312 0.624 129.419 0.635
202403 0.745 131.776 0.745

Add all the adjusted EPS together and divide 10 will get our e10.


Amphastar Pharmaceuticals  (FRA:29A) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Amphastar Pharmaceuticals's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=37.14/0.73
=50.88

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of Amphastar Pharmaceuticals was 114.20. The lowest was 14.35. And the median was 61.44.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Amphastar Pharmaceuticals E10 Related Terms

Thank you for viewing the detailed overview of Amphastar Pharmaceuticals's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Amphastar Pharmaceuticals (FRA:29A) Business Description

Traded in Other Exchanges
Address
11570 6th Street, Rancho Cucamonga, CA, USA, 91730
Amphastar Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the company sells insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has two reportable segments finished pharmaceutical products and API products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.

Amphastar Pharmaceuticals (FRA:29A) Headlines

No Headlines